Reply to “High frequency of Antiphospholipid Antibodies in Critically ill COVID‐19 patients: a Link with Hypercoagulability?”

Abstract

We have read with great interest the article recently published in your journal under the title 'High frequency of Antiphospholipid Antibodies in Critically ill COVID-19 patients: a Link with Hypercoagulability?' by Pinetron de Cambrun et al. [1]. This article retrospectively describes a series of 25 patients with acute respiratory distress syndrome (ARDS) associated with COVID-19 admitted to the ICU of a tertiary hospital. They found a high prevalence of antiphospholipid antibodies (aPL), which led them to suspect a specific induction of these aPL by SARS-CoV-2 and an association with the prothrombotic state triggered by this disease. Potential need for early anticoagulation therapy for all patients with COVID-19 is suggested on the basis of these findings.